Cargando…

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second‐line therapy: Results from the global DISCOVER study programme

AIM: To evaluate treatment data from DISCOVER (NCT02322762 and NCT02226822), a global, prospective, observational study programme of patients with type 2 diabetes initiating a second‐line glucose‐lowering therapy. MATERIALS AND METHODS: Data were collected using a standardized case report form. Firs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicolucci, Antonio, Charbonnel, Bernard, Gomes, Marília B., Khunti, Kamlesh, Kosiborod, Mikhail, Shestakova, Marina V., Shimomura, Iichiro, Watada, Hirotaka, Chen, Hungta, Cid‐Ruzafa, Javier, Fenici, Peter, Hammar, Niklas, Surmont, Filip, Tang, Fengming, Pocock, Stuart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852520/ https://www.ncbi.nlm.nih.gov/pubmed/31297947 http://dx.doi.org/10.1111/dom.13830

Ejemplares similares

Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

Glycaemic control in patients with type 2 diabetes initiating second‐line therapy: Results from the global DISCOVER study programme
por: Khunti, Kamlesh, et al.
Publicado: (2019)

Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme
por: Khunti, Kamlesh, et al.
Publicado: (2020)

Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study
por: Patel, Krishna K., et al.
Publicado: (2020)

Type 2 diabetes and heart failure: insights from the global DISCOVER study
por: Arnold, Suzanne V., et al.
Publicado: (2021)

Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global DISCOVER study
por: Charbonnel, Bernard H., et al.
Publicado: (2022)

Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study
por: Gomes, Marília B., et al.
Publicado: (2022)

Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
por: Bongaerts, Brenda, et al.
Publicado: (2021)

Impact of micro‐ and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort study
por: Arnold, Suzanne V., et al.
Publicado: (2022)

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
por: Arnold, Suzanne V., et al.
Publicado: (2022)

Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second‐line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany
por: Khunti, Kamlesh, et al.
Publicado: (2017)

Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
por: Pintat, Stéphane, et al.
Publicado: (2019)

Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review
por: Khunti, Kamlesh, et al.
Publicado: (2017)

Association of country economy and socioeconomic factors on risk factor control for primary prevention of cardiovascular disease in patients with diabetes mellitus: Insights from the DISCOVER study
por: Malik, Ali O., et al.
Publicado: (2022)

Rationale and Design for the J-DISCOVER Study: DISCOVERing the Treatment Reality of Type 2 Diabetes in a Real-World Setting in Japan—A Protocol
por: Katakami, Naoto, et al.
Publicado: (2017)

Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink
por: Wilding, John, et al.
Publicado: (2018)

Baseline Characteristics of Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: Findings from the J-DISCOVER Study
por: Katakami, Naoto, et al.
Publicado: (2020)

Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014
por: Caspard, Herve, et al.
Publicado: (2017)

Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry(®)
por: Arnold, Suzanne V., et al.
Publicado: (2017)

Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER
por: Takahara, Mitsuyoshi, et al.
Publicado: (2021)

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
por: Kosiborod, Mikhail, et al.
Publicado: (2017)

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall—a sub-analysis of the UTOPIA trial
por: Katakami, Naoto, et al.
Publicado: (2022)

Methods and rationale of the DISCOVER CKD global observational study
por: Pecoits-Filho, Roberto, et al.
Publicado: (2021)

Der Fliegende Holländer No. 668 : Le Vaisseau fantôme - The Flying Dutchman. Overture /

Dose-Dependent Effect of Sitagliptin on Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Post Hoc Analysis
por: Mita, Tomoya, et al.
Publicado: (2017)

The Effect of Sitagliptin on the Regression of Carotid Intima-Media Thickening in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation
por: Mita, Tomoya, et al.
Publicado: (2017)

Changes in carotid intima‐media thickening in patients with type 2 diabetes mellitus: Subanalysis of the Sitagliptin Preventive Study of Intima‐Media Thickness Evaluation
por: Mita, Tomoya, et al.
Publicado: (2017)

Results of 3,668 primary total hip replacements
por: Schreurs, BW, et al.
Publicado: (2012)

THU668 Euthyroid Graves’ Ophthalmopathy: Case Series
por: Saleh Alfadl, Sultan, et al.
Publicado: (2023)

Genome-wide identification of the DUF668 gene family in cotton and expression profiling analysis of GhDUF668 in Gossypium hirsutum under adverse stress
por: Zhao, Jieyin, et al.
Publicado: (2021)

The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis
por: Mita, Tomoya, et al.
Publicado: (2017)

Chronological Analysis With Fluorescent Timer Reveals Unique Features of Newly Generated β-Cells
por: Miyatsuka, Takeshi, et al.
Publicado: (2014)

Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial
por: Irie, Yoko, et al.
Publicado: (2018)

Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE)
por: Katakami, Naoto, et al.
Publicado: (2018)

Treatment patterns and satisfaction in patients with type 2 diabetes newly initiating oral monotherapy with antidiabetic drugs in Japan: results from the prospective Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND)
por: Tajima, Atsushi, et al.
Publicado: (2022)

Association of sodium‐glucose cotransporter‐2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD‐REAL 2 study
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

Proton Losses and estimated Radioactivity Levels, Runs 667, 668 and 676
por: Tausch, L, et al.
Publicado: (1976)

668. Restricting Ordering of Multiplex Gastrointestinal Panel Improves Test Utilization
por: Tai, Don Bambino Geno, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tl002ue942gcq2metrv3ju5ft8